Exploring the triple combination with venetoclax and azacitidine
Read moreOryzon Genomics announced today that the European Patent Office (EPO) has issued an “intention to grant” communication for Oryzon’s European patent application EP20712565.9 entitled “Methods o...
Read moreOryzon announced that it will present today the final data from its Phase IIb PORTICO trial of vafidemstat in patients with Borderline Personality Disorder (BPD) as an oral presentation at the New Med...
Read moreContrariamente al paradigma general de que la hipoxia favorece exclusivamente la progresión del tumor se encuentra que los niveles bajos de oxígeno en los tumores podrían potenciar algunas de las r...
Read moreOryzon Genomics announced today the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in Borderline Personality Disorder (BPD) with the US Food and Drug Adm...
Read moreEl equipo ha llegado a la conclusión de que la transformación maligna necesita reunir seis de las características epigenéticas en algún grado, desde cambios en el estado de metilación del ADN ha...
Read moreLos resultados sugieren el desarrollo de un sistema de predicción de recaídas mediante IA y el uso de la biopsia líquida para identificar y caracterizar pacientes con alto riesgo, lo que permitirá...
Read moreOryzon announced today that the European Patent Office (EPO) has now formally granted Oryzon’s European patent EP3661510B1, titled “Methods of treating behavior alterations” related to vafidemst...
Read moreInvestigadores del Cima Universidad de Navarra han descubierto que los niveles de PRMT5 están elevados en el colangiocarcinoma y que su aumento se relaciona con una enfermedad más avanzada
Read moreA research study led by the University of Barcelona describes how brain neurons in mice can be rejuvenated through a controlled cellular reprogramming cycle that helps to recover some altered neurolog...
Read moreOryzon Genomics, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the nine months...
Read moreThis patent protects a novel technology developed by Oryzon to measure the binding of LSD1 inhibitors such as iadademstat or vafidemstat to their therapeutic target, the epigenetic enzyme LSD1 (also k...
Read more